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Abstract
Increasing evidence suggests that the immune system affects prognosis of chronic myeloid leukemia (CML), but the detailed
immunological composition of the leukemia bone marrow (BM) microenvironment is unknown. We aimed to characterize
the immune landscape of the CML BM and predict the current treatment goal of tyrosine kinase inhibitor (TKI) therapy,
molecular remission 4.0 (MR4.0). Using multiplex immunohistochemistry (mIHC) and automated image analysis, we
studied BM tissues of CML patients (n= 56) and controls (n= 14) with a total of 30 immunophenotype markers essential in
cancer immunology. CML patients’ CD4+ and CD8+ T-cells expressed higher levels of putative exhaustion markers PD1,
TIM3, and CTLA4 when compared to control. PD1 expression was higher in BM compared to paired peripheral blood (PB)
samples, and decreased during TKI therapy. By combining clinical parameters and immune profiles, low CD4+ T-cell
proportion, high proportion of PD1+TIM3−CD8+ T cells, and high PB neutrophil count were most predictive of lower
MR4.0 likelihood. Low CD4+ T-cell proportion and high PB neutrophil counts predicted MR4.0 also in a validation cohort
(n= 52) analyzed with flow cytometry. In summary, the CML BM is characterized by immune suppression and immune
biomarkers predicted MR4.0, thus warranting further testing of immunomodulatory drugs in CML treatment.
Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative
disease driven by the BCR-ABL1 oncokinase as a result of
chromosomal translocation t(9;22) in myeloid stem cells of
the bone marrow (BM). Following the development of
tyrosine kinase inhibitors (TKI), the prognosis of chronic-
phase (CP) CML has improved. The principal aim of TKI
treatment is to achieve and maintain a deep molecular
response (MR) to prevent disease progression. Such
responses enable therapy discontinuation in a marked pro-
portion of patients, thus sparing potential side effects,
decrease in the quality of life, and escalating costs of
treatment [1, 2].
The BM constitutes the home niche for leukemic cells.
Its specific cellular and molecular structure remains
unknown, although increasing evidence suggests that the
immune system impacts the pathogenesis and prognosis of
CML patients [3–5]. Furthermore, TKIs have been shown to
induce immunomodulatory changes both in vivo and
in vitro [6]. A deep MR correlates with increased NK-cell
and CD8+ T-cell counts and cytotoxicity, and decreased
myeloid-derived suppressor cell (MDSC) counts in the
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peripheral blood (PB) of CML patients [7, 8]. In addition,
high CD62L+ T cells and low sCD62L+ have been sug-
gested to predict optimal treatment response to nilotinib [9].
Although it is difficult to prove the direct causal relationship
of the immune system and therapy response in patients, data
from TKI discontinuation studies suggest that immune
response is one of the important biological factors in suc-
cessful treatment-free remission (TFR) [1, 10–16]. For
example, the high proportion of CD56bright NK-cells, low
CD56dim NK-cell TNF-α/IFN-γ cytokine level, and high
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expression of CD86+ in plasmacytoid dendritic cells (pDC)
have been suggested as biomarkers predicting relapse after
TKI discontinuation [1, 10–12, 14].
Despite long-term remissions in many solid tumor types,
the therapeutic potential of immune checkpoint inhibitors in
CML, or in other hematological malignancies, has not been
fully evaluated. Here we present a comprehensive analysis
of immune cells in the BM of CP CML patients at diagnosis
using multiplexed immunohistochemistry (mIHC). In
addition, T-cell exhaustion status was determined at diag-
nosis and after 1, 3, and 6 months of TKI treatment in both
PB and BM with flow cytometry (FC). Based on the results,
we developed a novel risk stratification model predicting the
current treatment goal of TKI therapy, molecular response
4.0 (MR4.0), and compared that to stratification based on
the BCR-ABL International scale (IS) transcript level <10%
at 3 months [17]. The model was validated using FC.
Together, the findings provide a detailed understanding of
the immune landscape in CML BM and its clinical sig-




To examine immune cell numbers and their immunophe-
notype using mIHC, we collected all available diagnostic-
phase, pretreatment BM biopsies of CP CML patients
treated in the Department of Hematology, Helsinki Uni-
versity Central Hospital (HUCH) between 2005 and 2015
(n= 56). Patients with previous hematologic malignancy
were excluded. In addition, we recruited control subjects
with a BM biopsy taken in 2010 in HUCH (n= 14). The
most common biopsy indication was prolonged mild
thrombocytosis or anemia noticed at routine check-up
(Table S1). However, subjects presented no symptoms
and had neither previously or during 6 years of later follow-
up any hematologic malignancy, chronic infection nor
autoimmune disorder. All study subjects gave written
informed research consent to the study and to the Finnish
Hematology Registry. The study complied with the
Declaration of Helsinki and the HUCH ethics committee
(DNRO 303/13/03/01/2011).
FC validation cohort
To validate the covariates of the prediction model, we
recruited CML patients with a BM aspirate taken before
TKI treatment and from which T-cell proportions had been
analyzed with FC (n= 52). A more detailed T-cell immu-
nophenotype was not available as immune exhaustion
markers were not part of the clinical panel.
FC longitudinal cohort
To examine longitudinal changes in immune cell profiles,
we analyzed PB and BM aspirates of additional CML
patients (n= 16) during TKI therapy with FC. Immuno-
profiling experiments were performed once.
In total, three cohorts included 86 individual CML
patients.
Clinical data
In the ‘IHC cohort’, we assessed in total 47 clinical
diagnostic-phase baseline variables including pretreatment
laboratory exam values, spleen size, patient characteristics,
and medical history (Table S2). In addition, we used com-
plete cytogenetic response (CCyR), major molecular
response (MMR) and MR4.0 as treatment endpoints
according to ELN recommendations [18, 19]. The obser-
vation time in the cohorts was the interval between treat-
ment start to treatment response or last follow-up date.
Patients without treatment response were censored at the
last follow-up date. Competing risk analysis was not
required, as there were no frequent competing events.
Methods
Tissue microarrays (TMAs)
According to standard clinical procedure, fresh BM biopsies
were formalin-fixed and paraffin-embedded (FFPE) in the
Department of Pathology, HUSLAB at HUCH. Using
Fig. 1 a Overview of the analysis pipeline. Tissue microarrays
(TMAs) were constructed from duplicate bone marrow (BM) biopsy
punches of regions with high-leukemic infiltrates. TMA slides were
stained with multiplexed immunohistochemistry (mIHC) consisting of
5-plex fluorescent (PD1 [white], TIM3 [red], CD8 [green], CD4 [blue],
DAPI [gray]; left panel) and 3-plex chromogenic (CD3 [green],
FOXP3 [red] and hematoxylin counterstain; right panel) stainings. For
different antibody panels see Tables S3 and S4. Scanned histological
images are registered enabling analysis of marker localization. Cells
are segmented based on differential spatial intensity using Otsu
thresholding method. The intensity of each marker is quantified in
segmented cells and then classified. The various immunophenotypes
are aggregated for more detailed characterization and survival ana-
lyses. b Heatmap visualizing quantified immune cells (proportion of
all cells in a TMA spot) and their immunophenotypes (proportion of
the parent immune cell) organized by hierarchical clustering using
Spearman correlation distance and Ward linkage (ward.D2) method. c
The CML-to-control ratios of significantly varying (q < 0.05) median
values of each variable were transformed by twofold logarithmic
transformation and annotated according to the literature as anti-cancer
immunity (green) or immunosuppression marker (orange)
Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML 1645
hematopathologic expertize, we constructed FFPE TMA
blocks from duplicate 1 mm punches from areas with
highest leukemic cell infiltration in the BM biopsy (Fig. 1a).
Control spots were selected from the most representative
region.
Multiplexed immunohistochemistry (mIHC)
The mIHC method combines 5-plex fluorescence and 3-
plex chromogenic IHC. For antibody panels, see Tables S3
and S4. For original protocol, see Blom et al.[20] technical
protocol and Supplementary Methods.
Image analysis
Cell masks were segmented with parent immune cell mar-
kers (e.g., CD3 for T cells) using adaptive Otsu threshold-
ing, and individual cells separated from clumps using
intracellular intensity patterns. We used the image analysis
platform CellProfiler 2.1.2 for cell segmentation, intensity
measurements, and immune cell classification (Fig. 1a) [21–
23]. As CD34 is also an endothelial marker, vessel-like
structures were omitted from analysis. We computed total
cell numbers for each TMA spot from the total area of
binary DAPI images using Fiji. We computed marker co-
localization and cell classification with integrated intensity
using single-cell analysis (FlowJo v10; SI).
Spots with <1000 cells were excluded from analysis. To
exclude any bias due to varying cell numbers in different
TMA spots, different cell types were quantified as either
proportion to all cells (e.g., number of CD3+CD8+ T cells
to all cells in a TMA spot) or proportion of an immuno-
phenotype defined by 1–2 markers to the cell type of
interest (e.g., CD3+CD8+/PD1+TIM3+ T cells of all
CD3+CD8+ T cells). Two TMA spots from each CML and
control subjects were analyzed, and joined by the mean
value of each cell types and their immunophenotype.
Flow cytometry
FC validation cohort
Fresh diagnostic-phase BM aspirates (n= 52) were ana-
lyzed for CD3+, CD3+CD4+, and CD3+CD8+ cells
(Supplementary Methods). Their proportions were defined
from the remaining non-debris BM cells similarly as with
mIHC data.
FC longitudinal cohort
Vitally frozen mononuclear cells from PB and BM samples
were stained for longitudinal analysis (Supplementary
Methods).
Statistical analysis
To compare two groups of continuous variables, we used
Mann–Whitney U-test (unpaired, two-tailed), and
Kruskal–Wallis test for ≥3 groups. We excluded outliers
from comparison analyses with Grubbs’ test (alpha-value
0.2), and adjusted p-values using Benjamini&Hochberg’s
false discovery rate (FDR) correction (q < 0.05 corre-
sponding to p < 0.032 defined statistical significance) [24].
To compare continuous variables of two matched samples,
we used Wilcoxon signed-rank test (two-tailed). Statistical
associations between two continuous variables were asses-
sed with Spearman’s rank correlation coefficient. For clus-
tering analyses, data were z-scored and clustered by
Spearman correlation distance and Ward linkage (ward.D2)
methods.
To develop a model predicting TKI treatment efficacy
with minimal false discovery rate, we filtered first vari-
ables predicting MR4.0 using univariate Cox proportional-
hazards analysis. Significant variables (p < 0.05, log-rank
test) were included to an L1-penalized elastic net reg-
ularized regression analysis method that performs both
model shrinkage and variable selection [25, 26]. The
optimal shrinkage parameter lambda (λ) was computed by
the mean of iterated threefold crossvalidated (number of
iterations: 100) lambda.min (λ= 0.182) and lambda.1se (λ
= 0.318). The final model consisted of significant (log-
rank, p < 0.05) variables in multivariate model after
adjusting for TKI treatment (1st vs. 2nd generation TKI).
The proportional-hazards assumption of the model was
ensured with scaled Schoenfeld residuals. Models were
compared with area under the receiver operating char-
acteristic (AUROC) curve by bootstrapping (number of
bootstrap replicates: 4000), C-statistic and time-dependent
AUC (IPCW approach) [27]. We performed the statistical




The characteristics of the study patients are presented in
Table 1. The ‘IHC cohort’, the ‘FC validation cohort’
and the ‘FC longitudinal cohort’ were indifferent in
terms of patient age, gender, and prevalence of Sokal
and Hasford risk groups when compared to the ELN/
EUTOS CML registry ‘Out-study cohort’ used here as a
reference CML patient cohort [29]. The median age of
control subjects was 51 years (range 13–65 years) and
57% were male and is, thus, comparable with CML
patients in the ‘IHC cohort’. Although median age of
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control subjects is 6 years lower than CML patients, no
correlation between age and immunophenotype markers
could be found. The EUTOS low-risk group was over-
represented in the ‘FC longitudinal cohort’ and the
ELTS low-risk group in both FC cohorts when com-
pared to the ‘Out-study cohort’.
The first-line TKI varied between cohorts due to differ-
ence in participation in clinical studies comparing first-line
TKI and not to difference in disease burden. Time from
treatment start to MR4.0 was shorter in the ‘FC longitudinal
cohort’ than in other cohorts. The prevalence of BCR-ABL
<10% IS was equivalent in IHC and FC cohorts.
Multiplexed immunohistochemistry reveals an
immune suppression-skewed immune profile
in CML BM
To visualize integrated immune profiles of CML vs.
control BM, we mapped all immune cell subsets and their
single-marker phenotypes analyzed from the ‘IHC
cohort’ (Fig. 1a, b). Clustering analysis demonstrated that
immune cell subtypes associated with pro-inflammatory
anti-cancer immune response (e.g., proportion of CD3+
T cells, OX40+ and granzyme B producing (GrB+) CD8+
T cells) were decreased and immunosuppressive markers
(e.g., CTLA4+ CD4+ and CD8+ T cells, MDSC-like cells
and M2-type macrophages) increased in CML BM, group-
ing CML patients and control subjects distinctly from each
other.
Next, to identify most significant immunological para-
meters, we compared the expression levels of markers
defining either immune cell exhaustion or anti-cancer
immunity, and differing significantly (Mann–Whitney U-
test, q < 0.05) between CML vs. control BM subsets
(Fig. 1c). Immune cell subgroups and immunophenotype
markers associated with immune exhaustion were higher
and anti-cancer immunity markers lower in CML patients
than in control subjects.
T cells in CML BM display an exhausted phenotype
that partially resolves during TKI treatment
To further dissect the various CML immune profiles, we
focused on individual immune cell subsets and surface
marker profiles reflecting their functional states (Fig. 2a).
Due to myeloid expansion, lower proportion of CD3+,
CD3+CD4+, and CD3+CD8+ T cells from all cells were
observed in CML vs. control BM (Fig. 2b). In contrast, the
proportion of FOXP3+CD4+ regulatory T cells (Tregs)
and CD3–CD20+ B cells were enriched in CML vs. control
BM (Supplementary Figure 1A, and Fig. 3c). Moreover,
T cells were more frequently CD27− and CD45RO+ in
CML as compared to control suggesting increased differ-
entiation toward an effector memory phenotype (Fig. 2c and
Supplementary Figure 1C).
We next studied the expression of inhibitory (PD1,
TIM3, CTLA4, and LAG3) and activating (OX40) immune
checkpoint molecules in T cells. Higher PD1, TIM3, and
especially CTLA4 were observed in T cells of the CML vs.
control BM (Fig. 2d). Of particular interest, higher levels of
PD1+TIM3− in both CD4+ and CD8+ T cells (10.3%
IQR [7.0–15.6%] vs. 1.7% [0.95–3.0%], q< 0.0001, and
8.8% [5.6–14.0%] vs. 2.0% [1.0–5.1%], q < 0.0001,
respectively) and PD1+ TIM3+ (Fig. 2e) were observed in
CML vs. control BM. However, lower proportion of LAG3
was detected in both CD4+ and CD8+ T cells in CML as
compared to control BM (Supplementary Figure 1D).
Lower expression of the secondary co-stimulatory molecule
OX40 was noted in CD8+ T cells (9.0% [6.7––14.8%] vs.
16.0% [11.8–18.3%], q= 0.002), but not in CD4+ T cells
in CML vs. control BM. Finally, we found decreased pro-
duction of the cytolytic protein GrB and CD57 in T cells of
Table 1 Characteristics of the CML patients in the ‘IHC cohort’, and
in the confirmatory ‘FC validation’ and ‘FC longitudinal’ cohorts and





















52 [39–67] 51 [18–88]
Male, % 63 53 57 60
MR4.0 incidence, % 84 81 88 NA
Time from treatment start









TKIb, % 100 100 100 100
Imatinib, % 82 64 44 100
Dasatinib, % 11 17 31 0
Nilotinib, % 7 28 25 0
BCR-ABL <10% IS at
3 months, %
80 87 88 NA
Sokal score
Low, % 32 45 44 40
Intermediate, % 41 31 38 37
High, % 27 23 19 23
Hasford score
Low, % 36 45 31 42
Intermediate, % 52 41 56 47
High, % 13 15 13 12
EUTOS score
Low, % 86 87 94 87
High, % 14 13 6 13
ELTS score
Low, % 63 83 81 61
Intermediate, % 27 13 19 27
High, % 11 4 0 12
aThe ELN/EUTOS CML registry out-study patient cohort used for the
validation of the ELTS score is depicted here as a reference for patient
characteristics [13]
bFirst TKI after diagnosis
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CML patients, suggesting that the exhausted surface marker
phenotype is linked to decreased cytolytic activity (Sup-
plementary Figure 1A and B).
To test whether the BM represents a distinct milieu in
regard to T-cell phenotype and differentiation, we studied
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‘longitudinal FC cohort’. We found that both CD8+ and
CD4+ T cells had more pronounced PD1 expression in BM
vs. PB (26.9% vs. 12.7%, p= 0.001 and 18.9% vs. 10.4%,
p= 0.001, respectively; Fig. 2f–h). This difference was
significant in all T-cell subsets, including CD45RA-CCR7-
effector memory (TEM), CD45RA+CCR7− terminally
differentiated (TEMRA), CD45RA–CCR7+ central mem-
ory (TCM) and CD45RA+CCR7+ naive, with the highest
PD1 positivity in TEM and TEMRA cells (Fig. 2i). More-
over, the number of central memory CD4+ T cells and
naive CD8+ T cells was lower in BM (Fig. 2f, g).
Next, we evaluated PD1 expression on T cells during
TKI treatment in follow-up BM aspirates. We observed a
decrease in PD1+CD8+ but not CD4+ T cells at 1 and
3 months after the start of TKI therapy compared to diag-
nosis (27.1% vs. 21.6%, p= 0.009; Fig. 2j). The trend was
similar with all TKIs (imatinib, dasatinib, and nilotinib),
although statistical significance was not reached when
considering the TKIs individually due to sample size
(Fig. 2k). The reduction in PD1 expression was most pro-
minent in CD8+ TEM cells (Fig. 2i–k). Together, these
findings indicate that in CML patients, particularly the BM
milieu is associated with changes in T-cell populations, and
that an exhausted T-cell phenotype is partially resolved
during TKI therapy.
Increased immunosuppressive myeloid cells and
decreased class I HLA in CML BM
As the BM of TKI-naive CML patients demonstrated
immunosuppression in the lymphoid lineage, we investi-
gated next the composition and phenotype of myeloid cells.
Higher proportion of CD68+ myeloid cells from all cells
was observed in the CML BM compared to control subjects
(Fig. 3a). Interestingly, only the proportion of immuno-
suppressive cMAF+pSTAT1−CD68+ cells (M2-macro-
phages) was increased whereas cMAF-pSTAT1+CD68+
cells (M1-macrophages) remained equal in CML vs. control
BM (Fig. 3b). As MDSCs might be difficult to discern from
a CML background, we have annotated MDSC-like cells as
CD11b+CD33+HLADR- [30]. The proportion of MDSC-
like cells from all cells were elevated in CML vs. control
BM (Fig. 3a). Myeloid dendritic cells type 1 (mDC1) and
type 2 (mDC2) were characterized as CD11c+BDCA1+
and CD11c+BDCA3. To study dysfunction in antigen
presentation and mobility, we measured both the expression
level of class II HLA-DR and CD11b, respectively. Intri-
guingly, both mDC subpopulations, as well as their
expression of HLA-DR and CD11b were reduced in CML
vs. control BM (Fig. 3c, d).
At diagnosis, the majority of cells occupying the CP
CML BM are differentiated leukemic cells. However, fol-
lowing successful treatment only few CD34+ blasts remain
and normal hematopoiesis recovers. Thus, we compared the
expression of HLA class I molecules HLA-A, -B, and -C
(HLA-ABC) and inhibitory immune checkpoint ligands
PDL1/2 separately in CD34+ and all cells. We observed an
overall lower production of HLA-ABC in all BM cells but
higher HLA-ABC level in CD34+ cells when comparing
CML BM to control (Fig. 3e). Interestingly, HLA-ABC
expression was lower in CD34+ cells than in all BM cells
in both CML and control BM. Moreover, the expression of
PDL1/2 and the inhibitory class I HLA-G were higher in all
cells in CML vs. control BM (Fig. 3f). Analyzed by FC,
PD-L1 expression showed a trend toward elevated expres-
sion in BM CD34+ cells compared to peripheral circula-
tion, whereas no statistically significant difference to control
CD34+ was observed (Fig. 3g–i).
The proportion of helper T cells and PD1+TIM3–
cytotoxic T cells, and neutrophil count predict
MR4.0
Given the observed immune dysregulation associated with
CML, we aimed to understand the relation of the immune
profile to treatment responses and whether immunological
parameters can be used to predict responses. To stratify CML
patients by predisposition to reach MR4.0, we combined PB
and BM laboratory exam values, spleen size, patient
Fig. 2 The chronic myeloid leukemia (CML) bone marrow (BM) is
characterized by lymphoid-lineage immunosuppression. a Repre-
sentative example of cell gating based on marker intensity in ‘IHC
cohort’. Levels of b CD3+ T cells, CD4+ T cells, and CD8+ T cells,
c CD25 and CD27 expression in CD4+ and CD8+ T cells, and d PD1,
CTLA4, OX40, and TIM3 expression in CD4+ and CD8+ T cells
were compared with Mann–Whitney U-test after outlier exclusion
(Grubb’s test, alpha= 0.20), and p-values adjusted with Benjamini-
Hochberg procedure to reduce false discovery rate (q-values), and
results displayed with scatter plots. e Pie charts visualizing PD1 and
TIM3 expression in T-cell subgroups. f, g PD1, LAG3, and TIM3
expression and percentages of T-cell subsets in CD4+ and CD8+
T cells of paired BM and peripheral blood (PB) samples measured
(n= 11) by flow cytometry (FC). We defined CD45RA–CCR7– as
effector memory (EM) T cells, CD45RA+CCR7− as terminally dif-
ferentiated effector memory (TEMRA), CD45RA–CCR7+ as central
memory (CM) T cells, and CD45RA+CCR7+ as naive T cells. P-
values are calculated with Wilcoxon signed-rank test. h Representative
FC scatter plots of PD1 expression in CD3+CD8+ T cells from paired
BM and PB samples. i Heatmap of median percentage of PD1+ cells
out of indicated T-cell subsets in CML patients treated with imatinib
(n= 7) or dasatinib (n= 4). Rows are clustered using Spearman cor-
relation distance and Ward linkage (ward.D2) method. j Expression of
PD1 on CD4+ and CD8+ T cells in the BM at diagnosis and at
1 month (imatinib, dasatinib) or 3 months (nilotinib) after the start of
TKI treatment in paired FC samples in CML patients (n= 16). P-
values are calculated with Wilcoxon signed-rank test. k Expression of
PD1 in CD4+ and CD8+ T cells in the BM at diagnosis and different
time points during TKI treatment with imatinib (n= 7), dasatinib (n=
4) or nilotinib (n= 4) in CML patients. One dasatinib-treated patient
was excluded for missing data at 6 months. Points indicate median and
error bars represent interquartile ranges. * <0.05, ** <0.01, *** <0.001
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Fig. 3 The chronic myeloid leukemia (CML) bone marrow (BM) is
characterized by myeloid-lineage immunosuppression. Levels of (a)
CD68+ monocytes and CD33+CD11b+HLA–DR– myeloid-derived
suppressor cells, b CD68+/pSTAT1+cMAF– M1-macrophages and
CD68+/pSTAT1–cMAF+ M2-macrophages, c CD11c+BDCA1+
and CD11c+BDCA3+ myeloid dendritic cells type 1 (mDC1) and
type 2 (mDC2), respectively, and CD3–CD20+ B cells, d HLA-
DRhigh and CD11b+ expression in mDC1 and mDC2 cells, e HLA-
ABC expression in all BM cells and CD34+ stem cells, f and HLAG,
PDL1 and PDL2 expression in all BM cells of CML patients (n= 56)
and controls (n= 14) were compared with Mann–Whitney U-test after
outlier exclusion (Grubb’s test, alpha= 0.20), and p-values adjusted
with Benjamini-Hochberg procedure to compute false discovery rate
(q-values), and results displayed with scatter plots. g PDL1 and PDL2
expression on CD34+ cells of paired BM and PB samples of CML
patients (n= 5) measured by flow cytometry. P-values are calculated
with Wilcoxon signed-rank test. PDL1 (h) and PDL2 (i) expression on
CD34+ cells of unpaired BM and PB samples of CML patients (n=
11) and controls (n= 9) measured by flow cytometry. * <0.05, **
<0.01, *** <0.001
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demographics, and mIHC profiling data. To model the
coordinated interactions among multiple variables, we per-
formed an L1-penalized Cox regression analysis on variables
found significant in univariate Cox regression (log-rank p <
0.05), and visualized their similarities and dissimilarities using







Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML 1651
hierarchical clustering analysis (Table S5, Fig. 4a, b). Inter-
estingly, patients with high CD4+ T-cell proportion in the
BM were more inclined to achieve MR4.0 (Fig. 4b). In
subjects with low CD4+ T-cell proportion, HLA–ABC+
proportion in blasts correlated inversely with failure to reach
MR4.0, while markers of T-cell exhaustion, e.g., PD1+
TIM3– CD8+ T cells and PD1+OX40+CD4+ T cells, and
of disease burden, e.g., PB neutrophil count, correlated
positively with failure to reach MR4.0.
In the treatment of CP CML patients, 2nd generation
TKIs have been shown to be superior to imatinib in terms of
both treatment response and progression-free survival [31–
33]. Thus, we adjusted significant variables for TKI therapy
(1st vs. 2nd generation TKI) in multivariate Cox regression
analysis. The “CML immunology” model (“CMLi”) was
categorized to even-sized groups based on tertiles, e.g. the
low-risk, intermediate-risk (HR 2.8, p= 0.009, 95% CI
[1.3–6.0]), and high-risk (HR 12.8, p < 0.0001, 95% CI
[5.2–31.6]; Fig. 4c, d). The R2 of the categorized model was
0.45 (p < 0.0001). The CMLi model predicted MR4.0,
MMR, and CCyR using Cox regression analysis (log-rank
test, Fig. 4d). CMLi predicted TKI response superiorly than
stratification by BCR-ABL < 10% IS at 3 months using
time-dependent ROC (IPCW approach) and C-statistic, and
with a similar but non-significant trend using AUROC
(bootstrap method; Fig. 4e and Supplementary Figure 2).
Interestingly, the combination of both models and exclusion
of neutrophil count due to covariate insignificance improved
prediction performance further. The CMLi model also pre-
dicted MR4.0 with higher confidence than Sokal, Hasford,
and EUTOS scores using AUROC, but it should be noted
that these scores have not been developed to predict MR4.0
(Supplementary Figure 3).
To dissect the components of the CMLi model, we
computed univariate Cox regression analyses of individual
covariates using median as cutoff (Supplementary Fig-
ure 4). In addition, we studied the Spearman correlation of
the covariates of the CMLi model and clinical CML scores,
as well as with complete blood count (Supplementary Fig-
ure 5A). PB neutrophil count clustered with leukocyte count
and spleen size embodying disease burden. CD4+ T cells
correlated negatively with disease burden and positively
with the proportion of PB neutrophils and lymphocytes, and
with hemoglobin shown earlier to relate with leukemic stem
cell burden [34]. In addition, the proportion of PB eosino-
phils and basophils, platelet count, and patient age defined a
distinct group correlating weakly with other variables. We
identified lower T-cell proportion, higher PD1+ and OX40+
T cells (e.g., immune exhaustion and inflammation mar-
kers), as well as higher PB leukocyte count and lactate
dehydrogenase, (e.g., biomarkers of disease burden) as
clinicoimmunological variables associated with higher
CMLi risk group (Supplementary Figure 5B).
To validate the role of CD4+ T cells and neutrophils, we
analyzed fresh BM aspirates of the ‘FC validation cohort’.
Even in a small cohort of 52 patients, the proportion of CD4+
T cells and low neutrophil count significantly predicted faster
and more frequent MR4.0 (Fig. 5a–c). Interestingly, the trend
was similar with high proportion of CD3+ (HR 2.74, p=
0.003, log-rank test; CI 95% [1.38–5.44]), but not with CD8+
T cells (HR 1.53, p= 0.17; CI 95% [0.82–2.85]) and reaching
MR4.0 (Supplementary Figure 6).
Discussion
Our results suggest that the CML BM is analogous to solid
tumor microenvironment in having an immune landscape
with severe myeloid and lymphoid cell-mediated immuno-
suppression, which may partially resolve with successful
TKI treatment. In addition, we developed a novel risk
stratification model predicting TKI treatment response.
We aimed to clarify the clinical significance of the
immune landscape of CP CML patients, and therefore
focused on immune cells and checkpoint molecules with
known therapeutic potential in clinical trials. We applied a
novel mIHC technique combining six antibodies on a sin-
gle TMA slide. The major advantage of mIHC over con-
ventional FC is the possibility to analyze hundreds of
samples in parallel simultaneously and rapidly without
cryopreservation, which might affect cell number, viability
and phenotype [35]. We supplemented mIHC with auto-
mated image analysis to objectively classify and quantify
large numbers of immune cells, which would not have been
possible manually. As follow-up BM biopsies are not
sampled routinely, mIHC is not suited for routine hemato-
logical clinical work, but may substitute FC in academic
retrospective studies. Potentially, it can be applied in
oncology for biomarker discovery improving risk stratifi-
cation in clinical studies.
Fig. 4 Introduction of the chronic myeloid leukemia immunology
(CMLi) model. a Principal component analysis (PCA) plot of variables
selected with L1-penalized Cox regression model with top prediction
of molecular response 4.0 (MR4.0). b Significant covariates after
adjustment with TKI generation (imatinib vs. dasatinib or nilotinib) are
organized by hierarchical clustering using Spearman correlation dis-
tance and Ward linkage (ward.D2) method. c Summary of the CMLi
model computed with multivariate Cox regression analysis (log-rank
test). d The CMLi model was categorized into three even-sized sub-
groups and computed to predict (i) MR4.0, (ii) major molecular
response (MMR), and (iii) complete cytogenic remission (CCyR)
using Cox regression analysis. e The prediction power of the uncate-
gorized CMLi model to stratification by BCR-ABL < 10% IS at
3 months and their combination was measured with area under the
receiver operating characteristic curve (AUROC). The combined
model outperformed stratification by BCR-ABL < 10% IS at 3 months
(* <0.05, bootstrap method) HR hazard ratio. 95% CI 95% confidence
interval, Coef correlation coefficient
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Consistent with previous studies, MDSC-like cells and
M2-macrophages were more numerous in CML patients [7,
36, 37]. In addition, CD4+ and CD8+ T cells exhibited
higher levels of immune checkpoint receptors PD1, CTLA4,
and TIM3 in CML than in control BM. PD1 expression was
elevated in the BM T-cells compared to paired PB samples.
In addition, PD1 expression decreased in CD8+ T cells
during TKI treatment. The exhausted phenotype was asso-
ciated with lower expression of co-stimulatory marker
CD27, cytotoxicity marker GrB and activation marker OX40
in CML vs. control BM suggesting weaker CD8+ T-cell
cytotoxicity and activation, and elevated antigen-
experienced memory CD45RO+ T cells in CML.
Although these findings suggest marked immunosup-
pression in CML BM, it is unclear, whether they reflect a
direct adaptive immune response to leukemia cells or
chronic cytokine-induced inflammation by the myeloid cells
[38, 39]. Previously, PD1 and CTLA4 expression in T cells
have been shown to be increased at diagnosis and PD1 to
decrease with deepening MR status in PB samples of
untreated CML patients as elegantly demonstrated by
Hughes et al. [7, 36]. Moreover, in a murine CML model
the PD1 status of T cells has been associated with weaker
cytotoxic activity and cytokine production in vitro, and
blocking the PD1/PDL1 signaling improved survival sug-
gesting T-cells counteract disease progression [40]. This
study also suggests lower class I HLA expression to
desensitize CML stem cells from being identified by T cells.
Yet, the role of IFNγ secreted by activated lymphocytes
is paradoxical in CML. It has been shown that IFNγ pro-
motes myeloid expansion via the JAK2/STAT5 and ERK1/
2 pathways and decreases apoptosis by upregulating
RUNX1 [41]. Moreover, therapeutic adoptive T-cell infu-
sion alone increases CD34+ stem cell proliferation via a
IFNγ-mediated mechanism [42]. However, this effect could
be overrun by simultaneously blocking PD1/
PDL1 signaling emphasizing the protective role immune
checkpoint molecules confer on CML stem cells [43].
Most studies on CML immunology have been conducted
with PB samples. Our combined mIHC and FC analyses
suggest that the BM is a particularly immunosuppressive
microenvironment in CML, and should be the standard
tissue to study in future immuno-oncological studies.
Using L1-penalized regression modeling, we propose
low CD4+ T-cell proportion, high PD1+TIM3−CD8+ T-
cell proportion, and high PB neutrophil count as predictors
of weaker TKI treatment response. While the CMLi model
composed of baseline covariates might predict MR4.0 with
higher confidence than stratifying patients by BCR-ABL <
10% at 3 months, the combined model improves prediction
even further suggesting synergy. In addition, patients of
the CMLi high-risk group were associated with markers of
T-cell immunosuppression and greater tumor burden
defined by clinical parameters. Given the lack of immune
exhaustion markers in the ‘FC validation cohort’, the
multivariate CMLi model could not be validated com-
pletely. However, we confirmed both CD4+ T cell and PB
neutrophil counts as novel predictive biomarkers for
MR4.0 using fresh diagnostic-phase BM aspirate samples
analyzed by FC.
The immune system of CML patients with deep immu-
nosuppression might be incapable of killing cancer cells.
Fig. 5 Prediction of MR4.0 in
the ‘FC validation cohort’. a–c
Summary and survival curves of
univariate Cox regression
analysis (log-rank test) of CD4+
T cells analyzed from bone
marrow (BM) aspirates and
peripheral blood (PB)
neutrophils of the ‘FC validation
cohort’ (n= 52). HR hazard
ratio, 95% CI 95% confidence
interval
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We have shown that TKI treatment responses are more
potent in patients with less exhausted T cells. While
immune dysfunction might reflect disease aggressiveness,
and not inflict relative insensitivity to TKIs, the findings
could alternatively be explained by off-target immunomo-
dulatory effects of TKIs boosting pre-existing anti-leukemic
immune responses or dampening immunosuppressive cells
such as Tregs [6, 44]. Imatinib has for example been shown
to suppress the levels of immunosuppressive IDO expres-
sion in gastrointestinal stromal tumors, and dasatinib to
increase the number of cytotoxic cells in the circulation and
inside the tumors [6, 45–48].
In most solid tumors, T cells have been associated with
positive prognosis. This notion has led to the development
of the prognostic immunohistochemical tool ‘Immuno-
score’, which cannot be directly applied for leukemic
patients, as the BM lacks a clear invasive margin and central
tumor [49, 50]. Thus, we suggest that the combination of
clinical and immune cell parameters can be used as an
analogous prediction tool in CML.
In summary, the CMLi model highlights the role of
T cells and their immunophenotype, as well as disease
burden as critical predictive factors of TKI treatment
response in CP CML. Immunotherapeutic options should be
considered in CML treatment regimens as they might enable
molecular remission and treatment discontinuation. How-
ever, this hypothesis and CMLi cutoff values have to be
further validated in a multicenter study using FC.
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